Protara Therapeutics Inc is committed to advancing innovative therapies to address unmet medical needs in the field of rare diseases and oncology. The company's corporate philosophy centers around patient-centricity, scientific excellence, and a commitment to transforming lives through the development of cutting-edge treatments. Protara Therapeutics Inc values integrity, collaboration, and a passion for making a meaningful impact in the lives of patients and their families. Through its dedication to research, development, and commercialization, Protara Therapeutics Inc strives to create value and improve outcomes for those affected by serious and life-threatening diseases.

Protara Therapeutics Inc is primarily present in the United States.

Protara Therapeutics Inc has achieved several significant milestones. One of their notable achievements is the FDA approval of their lead drug candidate, TARA-002, for the treatment of lymphatic malformations. Additionally, the company has successfully completed Phase 1 clinical trials for TARA-002, demonstrating its safety and efficacy. Protara Therapeutics Inc has also expanded its pipeline by acquiring multiple preclinical stage assets, aiming to address unmet medical needs. Moreover, they have secured strategic partnerships and collaborations with renowned academic institutions and pharmaceutical companies to support their research and development efforts. These achievements highlight Protara Therapeutics Inc's commitment to advancing innovative therapies and improving patient outcomes in various disease areas.

Protara Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel therapies for rare and life-threatening diseases. Founded in 2017, Protara Therapeutics is dedicated to addressing unmet medical needs through innovative drug discovery and development. The company's research and development efforts are primarily centered around its proprietary technology platform, which allows for the design and optimization of potential novel therapies. With a commitment to improving patient outcomes, Protara Therapeutics aims to develop effective treatments for rare diseases and provide hope for patients and their families.

The main competitors of Protara Therapeutics Inc in the market include major pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson. These companies have established presence and resources in the biopharmaceutical industry, which poses competitive challenges for Protara Therapeutics Inc. Additionally, there are various smaller biotech companies focusing on similar therapeutic areas, including rare diseases and oncology, making the competitive landscape dynamic and diverse.

Protara Therapeutics Inc is primarily active in the biotechnology industry.

Protara Therapeutics Inc is a biopharmaceutical company focused on developing innovative treatments for rare and life-threatening diseases. The company's business model revolves around the research, development, and commercialization of novel therapies to address unmet medical needs. Protara Therapeutics Inc specializes in targeted protein degradation and immunology-based therapies, aiming to deliver transformative medicines for patients worldwide. With a strong commitment to strategic collaborations and comprehensive clinical trial programs, Protara Therapeutics Inc aims to bring groundbreaking therapies to market, improving patient outcomes and advancing healthcare in the process.

Az Protara Therapeutics P/E mutatója -0,54.

Az Protara Therapeutics KUV 0.

Az AlleAktien Minőségi Score Protara Therapeutics esetében 4/10.

A Protara Therapeutics esetében jelenleg nem számítható ki az árbevétel.

A(z) várt Protara Therapeutics nyereség -107,91 Mió. USD.

Protara Therapeutics Inc is a US-based biotech company headquartered in New York. It focuses on the development of novel therapeutics that can be used to treat various oncological, neuropathological, and immunological diseases. Protara utilizes innovative technologies to selectively release the active substances at the desired body locations. One of Protara's main divisions is oncology research. The company develops innovative therapeutics that help fight tumor cells while protecting healthy cells. Protara employs peptides that can selectively bind to tumor cells and release the active substances. This technology has the potential to significantly increase the effectiveness of cancer drugs while reducing their side effects. Another division of Protara is neuropathology research. Therapeutics are developed to treat various neurological diseases, including multiple sclerosis, Parkinson's, and Alzheimer's. Protara also utilizes innovative technologies to target the affected regions of the brain and release the active substances. The company collaborates closely with experts in neurology to develop the best possible therapeutics. The third division of Protara is immunology research. Therapeutics are developed to regulate and strengthen the immune system. The company uses peptides and other substances that can interact specifically with certain immune cells. This approach aims to effectively treat autoimmune diseases such as lupus or rheumatism. One important product of Protara is the medication MEDI9197, used to treat various solid tumors. The medication stimulates the immune system to recognize and fight tumor cells, effectively destroying them and reducing the risk of tumor-related inflammations. Protara's business model is based on the development of innovative therapeutics that improve patients' health using peptide-based substances. The company collaborates closely with researchers and experts from various fields to develop the best possible therapeutics. Protara also works closely with the academic world to benefit from the latest developments and knowledge. Moreover, it collaborates with the industry to translate its therapeutics into practical applications. Protara cooperates with various partners from the pharmaceutical and biotech industry to develop, produce, and market its therapeutics. In summary, Protara Therapeutics has a promising business model based on the development of innovative therapeutics. With its unique technology and a focus on collaboration with researchers and the industry, the company is well-positioned to continue growing and developing therapeutics that truly help patients.

A(z) Protara Therapeutics évente alkalommal oszt ki 0 USD összegű osztalékot.

A Protara Therapeutics esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Protara Therapeutics ISIN kódja: US74365U1079.

A Protara Therapeutics WKN-je A2P4JE.

Az Protara Therapeutics tőzsdei rövidítése TARA.

Az elmúlt 12 hónapban a(z) Protara Therapeutics osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Protara Therapeutics várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Protara Therapeutics jelenlegi osztalékhozama .

A(z) Protara Therapeutics negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Protara Therapeutics az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Protara Therapeutics a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Protara Therapeutics által 2024. 12. 26.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 12. 26.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 12. 26. időpontban történt.

2023 évben a Protara Therapeutics 0 USD összegű osztalékot fizetett ki.

Az Protara Therapeutics osztalékait USD fizeti ki.